Syneos Health announced an agreement to acquire Synteract, a full-service contract research organization (CRO) focused on the biopharmaceutical industry.

Cerevel Therapeutics began trading on the Nasdaq.

Eli Lilly and Company announced positive results from CENTURION, the company’s Phase III study looking into Reyvow (lasmiditan) for migraine attacks.

According to a study published in the journal Science Advances, an international team of researchers led by neuroscientists at Harvard Medical School uncovered which olfactory cell types are most vulnerable to infection by SARS-CoV-2, which causes Covid-19.

Dr. Reddy’s Laboratories Ltd. received approval for Elyxyb (celecoxib oral solution 25 mg/mL) from the U.S. Food and Drug Administration for the acute treatment of migraine with or without aura in adults.

Biogen filed a lawsuit against a New York life sciences company over alleged patent infringements related to the experimental Alzheimer’s disease treatment aducanumab.

The U.S. Food and Drug Administration has a busy week of possible drug approvals on the regulatory agency’s calendar, including Celgene’s ozanimod for relapsing forms of multiple sclerosis.

Dr. Ann McKee of Boston University studies the brains of deceased football players at the world’s largest brain bank, hoping to learn about the long-term impact of repeated head traumas for people ranging from professional athletes to victims of domestic abuse.

Eli Lilly priced the company’s acute migraine treatment Reyvow at $640 for a pack of eight pills.

Eli Lilly’s stock prices ticked up following the company’s announcement of strong quarterly sales and positive Phase III results in severe atopic dermatitis.